June 14, 2006 — Two new drugs overcome the resistance that can develop to the first-line-therapy imatinib ( Gleevec, Novartis) in chronic myeloid leukemia (CML), and results from phase 1 clinical ...
NEW YORK, June 5 (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel may be superior to the already highly effective standard medicine Gleevec in treating newly diagnosed patients with chronic ...
STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of ...
Single-agent activity of GCS-100, a first-in-class galectin-3 antagonist, in elderly patients with relapsed chronic lymphocytic leukemia This is an ASCO Meeting Abstract from the 2009 ASCO Annual ...
Patterns of imatinib resistance mutation analysis in chronic myeloid leukemia (CML) patients on imatinib at the time of loss of response to the drug in Asian Indian subjects No significant financial ...
The FDA's complete response letter for Dasynoc was due to manufacturing issues, delaying its approval for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) treatment. Dasynoc, a ...
DETROIT, October 16, 2025--(BUSINESS WIRE)--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC ...
PHYRAGO™ Represents the First and Only Improved Version of SPRYCEL ® That Can Be Safely Co-administered With Gastric Acid-Reducing Agents TAIPEI, TAIWAN / ACCESSWIRE / January 15, 2025 / ...
NEW YORK (Reuters) - Bristol-Myers Squibb's cancer drug Sprycel was superior to the highly effective Gleevec in treating newly diagnosed patients with chronic myeloid leukemia, researchers reported on ...
Cambridge-headquartered Cycle Pharmaceuticals has launched PHYRAGO, its first oncology product, in the US where it has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback